CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

Adult Solid Tumor Clinical Trial

— ANCERS-2  

Official title:

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03253575
• Other study ID #: MIT-201701
• Status: Suspended
• Start date: July 13, 2017
• Est. completion date: December 15, 2019

Study information

• Verified date: December 2018
• Source: Mitra RxDx, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug combinations) indicated for the stage and type of cancer for treatment. CANscript™ tests how a patients specific tumor reacts to the therapies being considered by the treating physician. CANscript™ test results have been shown to closely correspond with actual clinical results, providing physicians with information that may help him/her develop a more personalized cancer treatment and care plan based on the patients specific condition. The researchers want to see if CANscript™ test results are helpful in selecting the treatments prescribed and provided. There will be about 800 people taking part in this study, across 5 different tumor types. The study is designed to assess the decision impact of the CANscript™ test results in informing physicians in therapy selection.

Description:

This is an observational data collection study evaluating how physicians utilize therapeutic sensitivity information ascertained with CANscript, and subsequently describing clinical outcomes (clinical response and survival) resulting from their therapeutic selection.

Potential patients presenting for study enrollment will provide written informed consent and will subsequently be screened per inclusion/ exclusion criteria. Once enrolled, a biopsy & blood draw will be scheduled to obtain material for CANscript testing. Imaging will also be scheduled if a fresh image (obtained within 14 days of planned treatment initiation) is not available. Prior to submitting a fresh tissue sample for CANscript, the treating physician will select any number of therapies being considered for treatment, and will assign a priority ranking to those therapies (priority #1 through priority #N, with #1 representing their most preferred therapeutic option for the patient, and #N representing the number of their least preferred of the appropriate potential therapies). Prioritized therapies can be either single-agent therapeutics or combination regimens. All ranked therapeutic options must be available for individual patient at the time of selection. The prioritized list of preferred therapies will be sent to the testing laboratory (Mitra Biotech, Inc.) at least 2 days before the biopsy and blood draw are performed. Fresh tumor and blood samples will subsequently be sent to the testing laboratory for receipt within 24 hours of biopsy.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 800
• Est. completion date: December 15, 2019
• Est. primary completion date: July 31, 2019
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patient =18 years old

2. ECOG performance status of = 2

3. The patient's tumor must be amenable to a tumor biopsy sampling, so that CANscript can be performed

4. The patient must have disease that is measurable by standard imaging techniques, per the RECIST 1.1 (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation)

5. Histologically- or cytologically-confirmed:

A Locally advanced or metastatic HNSCC; B Locally advanced or metastatic TNBC; C Locally advanced or metastatic Stage 3b or 4 NSCLC after failure of appropriate 1st line therapy (i) Patients with EGFR or ALK mutations must have received previous appropriate therapy; D Locally advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, after failure of 1st line platinum-based chemotherapy (i) Recurrent or persistent stage 3 or 4 disease requiring relapse histologic documentation; E Stage IV metastatic CRC

6. Patient has signed informed consent prior to initiation of any study-specific procedures

Exclusion Criteria:

1. The patient has persistent clinically significant toxicities (Grade =2) from previous anticancer therapy (excluding chronic Grade 2 chemotherapy-related neuropathy which is permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).

2. The patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 14 days prior to study entry (42 days for prior nitrosourea or mitomycin-C). (Patients could have received supportive care therapeutics as appropriate).

3. The patient has an additional active malignancy that may confound the assessment of the study endpoints. Patients with a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including transitional cell carcinoma, cervical intraepithelial neoplasia), organ-confined prostate cancer with no evidence of progressive disease.

4. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).

5. The patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study.

6. The patient has known active or suspected brain or leptomeningeal metastases. (Central nervous system [CNS] imaging is not required prior to study entry unless there is a clinical suspicion of CNS involvement). Patients with stable, treated brain metastases are eligible provided there is no evidence of CNS disease growth on imaging for at least 6 weeks following radiation therapy or other loco-regional ablative therapy to the CNS.

7. The patient is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell). Corticosteroid therapy is permitted.

8. The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.

9. The patient is pregnant or breast-feeding. The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.

Related Conditions & MeSH terms

• Adult Solid Tumor

Intervention

Diagnostic Test:
• CANscript
CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.

Locations

Country	Name	City	State
United States	University of Colorado School of Medicine-Denver	Aurora	Colorado
United States	Austin Cancer Centers	Austin	Texas
United States	Lynn Cancer Institute	Boca Raton	Florida
United States	Doctors Hospital at Renaissance-DHR Health	Edinburg	Texas
United States	Southcoast Centers for Cancer Care	Fairhaven	Massachusetts
United States	Michigan Center of Medical Research -MHP	Farmington Hills	Michigan
United States	Broward Oncology Associates	Fort Lauderdale	Florida
United States	Holy Cross Hospital	Fort Lauderdale	Florida
United States	University of Texas Medical Branch at Galveston(UTMB)	Galveston	Texas
United States	Banner MD Anderson Cancer Center	Gilbert	Arizona
United States	St John Hospital and Medical Center (Great Lakes Cancer Managment Specialists)	Grosse Pointe Woods	Michigan
United States	Baylor College of Medicine Hemtology/Oncology	Houston	Texas
United States	Houston Methodist Medical Center	Houston	Texas
United States	Oncology Consultants	Houston	Texas
United States	The University of Texas Health Science Center at Houston- Hermann	Houston	Texas
United States	Joliet Oncology Associates	Joliet	Illinois
United States	Invesclinic US McAllen Oncology	McAllen	Texas
United States	University of Miami-Sylvester Comprehensive Cancer Center	Miami	Florida
United States	The Center for Gyencologic Oncology	Miramar	Florida
United States	Community Hospital	Munster	Indiana
United States	Edward Elmhurst Healthcare	Naperville	Illinois
United States	Saint Thomas Health	Nashville	Tennessee
United States	Ochsner Health System	New Orleans	Louisiana
United States	Eastern CT Hematology and Oncology Associates	Norwich	Connecticut
United States	Florida Hospital Cancer Institute	Orlando	Florida
United States	University of Rochester/Wilmot Cancer Institute	Rochester	New York
United States	Mercy Hospital	Saint Louis	Missouri
United States	War Memorial Hematology/Oncology	Sault Sainte-Marie	Michigan
United States	Memorial Health University Medical Center- Savannah Health Services	Savannah	Georgia
United States	Tallahassee Memorial Cancer Center	Tallahassee	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Mitra RxDx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CANscript decision impact will be captured via a study specific questionnaire	1. A questionnaire will be used to capture the information to be able to summarize the concordance and discordance rates between: Empirically selected therapy (selected by treating physicians prior to knowing the CANscript results for a given patient) and CANscript recommended therapy (i.e., the therapy with the highest CANscript M-score for a given patient).; Empirically selected therapy and CANscript results that predict response or non-response.	18-24 months
Secondary	The RECIST 1.1 criteria will utilized to assess therapy response, i.e. Complete Response (CR), Partial Response (PR), Stable Disease (SD), Duration of Response (DoR), Progression Free Survival (PFS)	A baseline Image will be taken prior to therapy initiation, and then as per tratment guidelines throughout and following therapy delivery: 1. To summarize tumor response in terms of objective response rate (ORR), clinical benefit rate (CBR), duration of response (DoR) progression-free survival (PFS), and overall survival (OS) based on imaging (CT, MRI, etc.) and scoring per RECIST 1.1 criteria.	24-48 months